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Background. Tuberculosis immune reconstitution inﬂammatory syndrome (IRIS) is a common cause of dete-
rioration in human immunodeﬁciency virus (HIV)–infected patients receiving tuberculosis treatment after starting
antiretroviral therapy (ART). Potentially life-threatening neurological involvement occurs frequently and has been
suggested as a reason to defer ART.
Methods. We conducted a prospective study of HIV-infected, ART-naive patients with tuberculous meningitis
(TBM). At presentation, patients started tuberculosis treatment and prednisone; ART was initiated 2 weeks later.
Clinical and laboratory ﬁndings were compared between patients who developed TBM-IRIS (TBM-IRIS patients)
and those who did not (non-TBM-IRIS patients). A logistic regression model was developed to predict TBM-IRIS.
Results. Forty-seven percent (16/34) of TBM patients developed TBM-IRIS, which manifested with severe
features of inﬂammation. At TBM diagnosis, TBM-IRIS patients had higher cerebrospinal ﬂuid (CSF) neutrophil
counts compared with non-TBM-IRIS patients (median, 50 vs 3 cells ×106/L, P = .02). Mycobacterium tuberculosis
was cultured from CSF of 15 TBM-IRIS patients (94%) compared with 6 non-TBM-IRIS patients (33%) at time of
TBM diagnosis; relative risk of developing TBM-IRIS if CSF was Mycobacterium tuberculosis culture positive = 9.3
(95% conﬁdence interval [CI], 1.4–62.2). The combination of high CSF tumor necrosis factor (TNF)-α and low
interferon (IFN)-γ at TBM diagnosis predicted TBM-IRIS (area under the curve = 0.91 [95% CI, .53–.99]).
Conclusions. TBM-IRIS is a frequent, severe complication of ART in HIV-associated TBM and is character-
ized by high CSF neutrophil counts and Mycobacterium tuberculosis culture positivity at TBM presentation. The
combination of CSF IFN-γ and TNF-α concentrations may predict TBM-IRIS and thereby be a means to individ-
ualize patients to early or deferred ART.
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Paradoxical tuberculosis immune reconstitution in-
ﬂammatory syndrome (IRIS) occurs in 8%–43% of
human immunodeﬁciency virus (HIV)–infected pa-
tients receiving tuberculosis treatment after starting
antiretroviral therapy (ART) [1–4]. Tuberculosis IRIS
results from rapid restoration of Mycobacterium
tuberculosis–speciﬁc immune responses, but its patho-
genesis remains poorly understood [1, 5, 6].
Neurological tuberculosis IRIS occurs in a substan-
tial proportion (12%) of tuberculosis IRIS cases and is
the commonest cause of central nervous system (CNS)
deterioration during the ﬁrst year of ART in settings
of high tuberculosis/HIV prevalence [7, 8]. Mortality is
high (up to 30%) in those affected [8]. Manifestations
of neurological tuberculosis IRIS include meningitis
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[7–11], intracranial tuberculomata [7, 8, 12–14], brain abscess-
es [12, 15], radiculomyelitis [7, 8, 11], and spinal epidural ab-
scesses [7]. There are no prospective studies describing
tuberculous meningitis (TBM) IRIS; only isolated cases [9–15]
and 1 case series of neurological tuberculosis IRIS [8, 16] have
been published. Although consensus now exists that ART
should be started early (around 2 weeks) in HIV/tuberculosis-
coinfected patients with severe immunosuppression, a poten-
tial exception is TBM because of the perceived risk of TBM-
IRIS [17, 18]. However, the frequency and severity of this
complication are not well documented and no means exist to
predict the syndrome.
We therefore investigated clinical and laboratory ﬁndings in
ART-naive HIV-infected patients who presented with TBM.
We undertook serial cerebrospinal ﬂuid (CSF) sampling in pa-
tients who did and did not develop TBM-IRIS.
MATERIALS AND METHODS
Setting
This prospective, observational study was performed at GF
Jooste Hospital, a public sector referral hospital in Cape
Town.Thehospital servesa low-income,high-densitypopulation
in which the tuberculosis notiﬁcation rate exceeds 1.5% per
year with 70% of tuberculosis cases coinfected with HIV [19].
Participants
ART-naive HIV-infected patients aged ≥18 years presenting
with meningitis from March 2009 through October 2010 were
screened for study inclusion. HIV infection was diagnosed using
2 rapid HIV antibody tests and conﬁrmed by HIV load. Deﬁnite
TBM was diagnosed when acid-fast bacilli were seen, or when
M. tuberculosis was cultured from CSF. Probable TBM was diag-
nosed when a patient showed clinical, laboratory, and radiologi-
cal features of TBM in the absence of other infective causes for
presentation [20]. Paradoxical TBM-IRIS was diagnosed accord-
ing to a published deﬁnition for tuberculosis IRIS modiﬁed for
meningitis [7, 8]. The deﬁnition had 3 components: (1) TBM
diagnosis before starting ART and improvement on tuberculosis
treatment prior to ART initiation; (2) onset of TBM-IRIS mani-
festations (ie, new, recurrent, or worsening clinical features of
TBM) within 3 months of ART initiation; and (3) exclusion of
alternative causes for clinical deterioration.
Patients were ineligible if they had a contraindication to
lumbar puncture, including unequal pressures between individ-
ual brain compartments on brain imaging, or severe TBM (ie,
modiﬁed British Medical Research Council [BMRC] grade III
disease severity) [21]. The University of Cape Town Research
Ethics Committee approved the study and written informed
consent was obtained from all patients or their relatives.
Procedures
Demographic data and history of tuberculosis disease, HIV
infection, and other systemic illnesses and medications were
recorded. Patients underwent general physical and
neurological examination. Chest radiography, phlebotomy, and
lumbar puncture were performed. In patients with suspected
raised intracranial pressure or focal neurological deﬁcits, brain
computed tomography scanning was performed prior to
lumbar puncture. CSF analysis included biochemistry, cytolo-
gy, microbiology (including microscopy and culture for fungi
and pyogenic bacteria), syphilis serology, HIV load, and Cryp-
tococcus latex agglutination titer. Ziehl-Neelsen staining of
sediment and M. tuberculosis culture was performed. If myco-
bacteria were cultured from CSF, tuberculosis polymerase
chain reaction (PCR; Genotype MTBDRplus, Hain Lifesciences)
was performed to determine susceptibility to rifampicin and
isoniazid. CSF varicella zoster virus PCR was performed if the
etiology was suspected. CSF was also stored at −80°C and
analyzed for a range of inﬂammatory markers on the Bio-Plex
platform (Bio-Rad Laboratories, Hercules, CA) using custom-
ized Milliplex kits (Millipore, St Charles, MO) according to the
manufacturer’s instructions.
At TBM diagnosis, patients started tuberculosis treatment
according to national guidelines [22] and prednisone (1.5 mg/
kg/day). After 2 weeks of treatment and prior to initiation of
ART, patients were assessed for improvement on tuberculosis
treatment. The initial ART regimen was stavudine, lamivu-
dine, and efavirenz. Later during the study, tenofovir replaced
stavudine according to revised national guidelines. CSF inves-
tigations performed at TBM diagnosis were repeated at the
time of ART initiation, 2 weeks later, and at time of TBM-
IRIS presentation and 2 weeks thereafter. Prednisone was
reduced to 0.75 mg/kg/day 4 weeks after starting ART and dis-
continued 2 weeks thereafter, unless the patient developed
TBM-IRIS. At TBM-IRIS presentation, investigations were
performed to exclude alternative causes of deterioration. Pred-
nisone was either recommenced or the dose increased. Pa-
tients were followed for the duration of tuberculosis treatment
(9 months); routine visits were at 2 weeks, 4 weeks, 6 weeks,
12 weeks, 6 months, and 9 months after TBM diagnosis. Pa-
tients were seen more frequently during deterioration.
Statistical Analysis
Statistical analysis was performed using the GraphPad Prism
version 5, R version 2.14.1, and StatXact version 9 software
packages. Categorical variables were compared using χ2 or
Fisher exact test. Continuous variables were compared between
groups and time points within groups, using the Wilcoxon
rank sum and Wilcoxon matched pairs tests, respectively.
Adjusted relative risks (RRs) were evaluated using Cochran-
Mantel-Haenszel tests and tests of homogeneity when
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considering categorical risk factors. Log-binomial models were
ﬁtted to continuous risk factors. Signiﬁcance testing was done
using 2-sided P values with P < .05 taken as signiﬁcant.
The predictive accuracy of CSF neutrophil counts at TBM
diagnosis for TBM-IRIS was assessed using nonparametric area
under the receiver operating characteristic curve (AUC). Addi-
tionally, a model to predict TBM-IRIS risk was developed from
5 prespeciﬁed cytokines measured in CSF at time of TBM diag-
nosis. Interleukin 6 (IL-6), interleukin 10, interleukin 12p40,
interferon gamma (IFN-γ), and tumor necrosis factor alpha
(TNF-α) were selected as candidate markers of TBM-IRIS
based on previous studies [23, 24]. We prespeciﬁed the analysis
for evaluating the multivariate cytokine model as follows. Sig-
niﬁcant cytokines comparing TBM-IRIS and non-TBM-IRIS
using Wilcoxon rank sum tests were selected for a logistic
regression model. Nonsigniﬁcant cytokines were dropped,
resulting in a ﬁnal model. The entire model building process
was evaluated using leave-one-out cross-validation, the boot-
strap method [25], and the permutation test to provide a cross-
validated (nonparametric) estimate of the AUC, P values, and
95% conﬁdence intervals (CIs). As a secondary analysis, we ex-
amined whether the addition of CSF neutrophils and/or lym-
phocyte counts would improve the model’s predictive ability.
RESULTS
TBM Presentation
The ﬁnal diagnoses and reasons for exclusion of patients with
meningitis are shown in Figure 1. Thirty-four patients were
included in the ﬁnal analysis; 15 (44%) were female and the
median age was 33 years (interquartile range [IQR], 29–44).
Sixteen patients (47%) developed TBM-IRIS (TBM-IRIS
Figure 1. Flow diagram of patients with features of meningitis (eg, headache, confusion, vomiting, and/or neck stiffness) screened for study inclusion.
aPatients defaulted within 3 months of starting antiretroviral therapy (ART). bTime points of lumbar punctures include tuberculous meningitis (TBM)
diagnosis, ART initiation, and 2 weeks after starting ART. cCerebrospinal ﬂuid varicella-zoster virus polymerase chain reaction was performed in 1
patient with who had shingles at time of TBM presentation, which was positive. Abbreviations: ART; antiretroviral therapy, IRIS; immune reconstitution
inﬂammatory syndrome; TB; tuberculosis; TBM, tuberculous meningitis.
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patients) whereas 18 did not (non-TBM-IRIS patients).
Tables 1 and 2 show the demographic and baseline character-
istics of these 2 groups. Baseline characteristics were similar
between groups, although patients who developed TBM-IRIS
had a longer duration of symptoms (median, 19 vs 9 days)
and more frequent features of extrameningeal tuberculosis,
such as chest symptoms (81% vs 44%) and chest radiographic
abnormalities (81% vs 50%). Five TBM-IRIS patients (31%)
and 3 non-TBM-IRIS patients (17%) developed features of
extrameningeal tuberculosis IRIS.
TBM-IRIS Presentation
Features of TBM-IRIS developed a median of 14 days (IQR,
4–20) after starting ART. Symptoms and signs included new
or worsening headache (n = 12), confusion (n = 6), neck pain/
stiffness (n = 11), generalized tonic-clonic seizures (n = 4),
Table 1. Demographic and Baseline Characteristics of Patients Who Developed Tuberculous Meningitis Immune Reconstitution In-
ﬂammatory Syndrome and Those Who Did Not
TBM-IRIS Non-TBM-IRIS
No. (%) No. (%)
Female 9 (56) 6 (33)
Age, y, median (IQR) 33 (30–46) 31 (25–41)
Duration between tuberculosis treatment and ART, d, median (IQR)a 15 (14–16) 15 (14–20)
Previous tuberculosis 5 (31) 6 (33)
Neurological symptoms
Duration of neurological symptoms, d, median (IQR) 19 (6–31) 9 (6–21)
Nausea/vomiting 13 (81) 8 (44)
Headache 16 (100) 14 (78)
Visual disturbances 6 (38) 5 (28)
Confusion 7 (44) 6 (33)
Neck pain/stiffness 13 (81) 14 (78)
Systemic symptoms
Chest symptoms 13 (81) 8 (44)
Night sweats 12 (75) 8 (44)
Abdominal symptoms 9 (56) 5 (28)
Weight loss 14 (88) 12 (67)
Clinical findings
Body mass index, median (IQR) 18.4 (17.2–23.3) 20.7 (19.0–23.3)
BMRC disease grade 1b 7 (44) 11 (61)
Focal neurological signsc 4 (25) 3 (17)
Blood investigations
Sodium, mmol/L, median (IQR) 123 (121–129) 130 (128–134)
Hemoglobin, g/dL, median (IQR) 10.2 (8.5–11.7) 12.4 (9.3–13.4)
Other investigations
CXR abnormalities 13 (81) 9 (50)
Features of extra CNS tuberculosisd 14 (88) 12 (67)
Abdominal ultrasound, abnormal/number performed 5/5 (100) 6/8 (75)
Brain CT abnormal/number performede 4/5 (80) 5/9 (56)
Data are presented as No. (%) unless otherwise specified. Definitions for TBM-IRIS and non-TBM-IRIS are taken from [16] and [18], respectively.
Abbreviations: ART, antiretroviral therapy; BMRC, British Medical Research Council; CNS, central nervous system; CT, computed tomography; CXR, chest
radiograph; IQR, interquartile range; TBM-IRIS, tuberculous meningitis immune reconstitution inflammatory syndrome.
a ART regimens included stavudine (D4T), lamivudine (3TC), and efavirenz (EFV; n = 19); tenofovir, 3TC, and EFV (n = 9); zidovudine, 3TC, and EFV (n = 5); and
D4T, 3TC, and lopinavir/ritonavir (n = 1).
b BMRC grade I: Glasgow Coma Scale (GCS) score of 15 with no focal neurologic signs; grade II: GCS score of 11–14 or GCS of 15 with focal neurologic signs;
grade III: GCS score of ≤10 [21].
c Including cranial nerve palsies (n = 4), hemiparesis (n = 1), cerebellar signs (n = 2).
d Including number of patients with 1 or more of the following: chest radiograph or abdominal ultrasound features of tuberculosis and acid-fast bacilli seen or
M. tuberculosis cultured from specimen other than cerebrospinal fluid.
e Including features compatible with TBM: hydrocephalus, meningeal enhancement, tuberculoma, and infarct.
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Table 2. Serial Blood and Cerebrospinal Fluid Findings in Patients Who Developed Tuberculous Meningitis Immune Reconstitution
Inﬂammatory Syndrome (TBM-IRIS) and Those Who Did Not (non-TBM-IRIS)
TBM-IRIS Non-TBM-IRIS
Median (IQR) Median (IQR) P Valuec
Blood
C-reactive protein, mg/L
TBM diagnosis 45 (13–98) 25 (1–71) .22
ART start 6 (4–15) 8 (1–20) .64
2 wk after ART start 56 (20–105) 14 (6–63) .07
CD4 count, cells/μL
TBM diagnosis 131 (52–169) 102 (69–278) .79
ART start 93 (65–158) 145 (64–231) .40
2 wk after ART start 158 (139–193) 178 (103–261) .68
HIV load, log10
TBM diagnosis 5.39 (4.75–6.16) 5.60 (4.76–5.72) .83
ART start 5.61 (5.26–6.26) 5.30 (4.90–6.04) .13
2 wk after ART start 3.15 (2.50–3.36) 2.71 (2.43–2.98) .13
Cerebrospinal fluid
Protein, g/L
TBM diagnosis 2.70 (1.80–5.11) 1.88 (1.28–3.31) .24
ART start 1.63 (1.22–2.67) 0.94 (0.82–1.63) .03
2 wk after ART start/IRIS presentationa 3.11 (1.99–22.83) 0.61 (0.37–1.76) <.001
2 wk after IRIS presentationb 2.62 (2.24–12.74) … …
Glucose (CSF blood ratio)
TBM diagnosis 0.24 (0.15–0.31) 0.47 (0.28–0.57) .01
ART start 0.51 (0.43–0.55) 0.48 (0.38–0.57) .63
2 wk after ART start/IRIS presentationa 0.39 (0.33–0.43) 0.53 (0.37–0.59) .05
2 wk after IRIS presentationb 0.38 (0.34–0.48) … …
Neutrophil counts, ×106/L
TBM diagnosis 50 (15–86) 3 (0–44) .02
ART start 1 (0–4) 0 (0–5) .32
2 wk after ART start/IRIS presentationa 42 (17–244) 0 (0–3) <.001
2 wk after IRIS presentationb 3 (0–12) … …
Neutrophil proportion, % of cells per sample
TBM diagnosis 36 (6–53) 0 (0–12) .009
ART start 1 (1–11) 0 (0–18) .61
2 wk after ART start/IRIS presentationa 9 (4–22) 1 (0–33) .35
Lymphocyte counts, ×106/L
TBM diagnosis 218 (63–366) 93 (24–274) .36
ART start 110 (44–225) 41 (18–79) .02
2 wk after ART start/IRIS presentationa 177 (69–363) 25 (6–52) <.001
2 wk after IRIS presentationb 147 (98–405) … …
HIV load, log10
TBM diagnosis 6.35 (5.80–6.73) 5.60 (4.81–6.54) .05
ART start 5.56 (5.16–5.95) 5.40 (4.93–5.82) .27
2 wk after ART start 3.00 (2.24–3.67) 2.55 (2.42–2.80) .21
Definitions for TBM-IRIS and non-TBM-IRIS are taken from [16] and [18], respectively.
Abbreviations: ART, antiretroviral therapy; CSF, cerebrospinal fluid; HIV, human immunodeficiency virus; IQR, interquartile range; IRIS, immune reconstitution
inflammatory syndrome; TBM, tuberculous meningitis.
a For TBM-IRIS patients, results are reported for lumbar puncture performed at TBM-IRIS presentation, which occurred a median of 14 days after ART initiation.
b In 5 TBM-IRIS patients, lumbar puncture was not performed 2 weeks after TBM-IRIS because of death (n = 1), contraindication to lumbar puncture (n = 3), and
patient admitted to alternative facility (n = 1).
c P < .05 was considered statistically significant.
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vomiting (n = 5), paraparesis (n = 3), myoclonic jerks (n = 1),
dysconjugate eye movements (n = 1), and aphasia (n = 1). At
time of TBM-IRIS presentation, 15 patients underwent brain
imaging, including computed tomography (n = 14) or magnet-
ic resonance imaging (n = 1). Imaging showed features of
TBM in 14 of these patients. Magnetic resonance imaging of
the spine was performed in 2 patients with paraparesis; both
had features of radiculomyelitis (Supplementary Figure 1).
Serial Blood and CSF Findings
Baseline blood investigations were similar between TBM-IRIS
and non-TBM-IRIS patients with the exception of serum
sodium concentrations, which were lower in TBM-IRIS pa-
tients (median, 123 vs 130 mmol/L, P = .01, Table 1). Table 2
and Figure 2 show serial blood and CSF ﬁndings. There was a
signiﬁcant rise in CD4 counts between starting ART and 2
weeks later in both TBM-IRIS (median, 93–158 cells/μL,
P = .009) and non-TBM-IRIS (median, 145–178 cells/μL,
P = .04) patients. Between these time points, blood and CSF
HIV loads decreased signiﬁcantly (P < .001) in both groups.
At TBM diagnosis, TBM-IRIS patients had higher CSF cell
counts, in particular neutrophils (median, 50 vs 3 cells ×106/L,
P = .02, Table 2). Similarly, neutrophil percentages from indi-
vidual samples were higher in TBM-IRIS patients compared
with non-TBM-IRIS patients (median, 36% vs 0%, P = .009).
CSF to blood glucose ratios were lower in TBM-IRIS patients
(median, 0.24 vs 0.47, P = .005). In both groups, CSF parame-
ters initially improved on tuberculosis treatment (Table 2 and
Figure 2). However, at TBM-IRIS presentation, TBM-IRIS pa-
tients showed ﬁndings of recurrent inﬂammation. In this
group, lymphocyte and neutrophil counts at TBM-IRIS pre-
sentation were similar, and protein concentrations higher,
compared with the same parameters at TBM diagnosis
(median protein, 3.11 g/L at TBM-IRIS vs 2.70 g/L at TBM
diagnosis, P = .007).
Mycobacterium tuberculosis was cultured from the CSF of
15 TBM-IRIS patients (94%) and 6 non-TBM-IRIS patients
(33%) at TBM diagnosis; the risk of developing TBM-IRIS if
CSF M. tuberculosis culture was positive at this time point was
71.4% (15/21), compared with a risk of 7.7% (1/13), corre-
sponding to an RR of 9.3 (95% CI, 1.4–62.2, P = .004). Addi-
tional analyses considered the RRs of culture positivity
adjusting for the following known or potential risk factors for
tuberculosis IRIS: baseline viral load (median, ≥330 000
copies/mL, equivalent to log10 = 5.52, vs <330 000), CD4
count (median, ≤137 cells/μL vs >137), evidence of dissemi-
nated disease in the form of an abnormal chest radiograph
suggesting miliary disease, and duration of illness (median du-
ration, ≥2 weeks vs <2 weeks). Mycobacterium tuberculosis
culture positivity remained a signiﬁcant risk factor after ad-
justing for these factors (Supplementary Table 1). There was
no evidence of differences in the RRs according to these
factors after considering culture status. Some TBM-IRIS pa-
tients remained culture positive after 2 weeks (n = 7) and 4
weeks (n = 2) of tuberculosis treatment. No non-TBM-IRIS
patients were culture positive after starting tuberculosis treat-
ment. All cultures were fully drug sensitive with the exception
of one, which was monoresistant to isoniazid.
Analysis of Baseline CSF Neutrophil Count and Cytokine
Concentrations to Predict TBM-IRIS
Concentrations of the prespeciﬁed cytokines from which the
model to predict TBM-IRIS was developed are shown in Sup-
plementary Table 2 and Supplementary Figure 2. The ﬁnal
multivariate logistic regression model included IFN-γ and
TNF-α and produced a cross-validated AUC of 0.91 (95% CI,
.53–.99, P = .02), indicating high diagnostic accuracy when
jointly considering these 2 cytokines to differentiate TBM-
IRIS from non-TBM-IRIS at time of TBM diagnosis. The
odds ratio (OR) for TNF-α was 1.85 (per 10 pg/mL, P = .006),
indicating an 85% increase in the odds of IRIS for every 10
pg/mL increase in TNF-α (after adjusting for IFN-γ). The OR
for IFN-γ was 0.64 (per 100 pg/mL, P = .01), indicating de-
creased odds of IRIS with increasing IFN-γ (after adjusting for
TNF-α). Figure 3 provides a heatmap representation of the
predicted probabilities of the resulting model with the ob-
served values overlaid. Neutrophil counts produced an AUC
of 0.72 (95% CI, .54–.90, P = .03), indicating modest discrimi-
natory accuracy for TBM-IRIS. However, including CSF neu-
trophil and lymphocyte counts in the model did not improve
its ability to predict TBM-IRIS.
Management and Outcome
In 13 patients prescribed prednisone (0.75–1.5 mg/kg/day),
the dose was increased at TBM-IRIS diagnosis. Prednisone
was restarted at a dose of 1.5 mg/kg/day in the other 3 TBM-
IRIS patients. The median total duration of corticosteroid
treatment in TBM-IRIS patients was 109 days (IQR, 69–141)
compared with 35 days (IQR, 20–43) in non-TBM-IRIS pa-
tients. ART was interrupted during TBM-IRIS in 1 patient
because of brainstem involvement. This patient made a full
recovery and had no recurrent symptoms after recommence-
ment of ART under prednisone cover. At 9 months’ follow-
up, all non-TBM-IRIS patients were alive (including 1 who
had defaulted study follow-up but continued tuberculosis
treatment from a primary care tuberculosis clinic), 2 had
marked cognitive impairment (international HIV dementia
scale <10) [26], and 1 patient had marked cognitive impair-
ment with residual hemiparesis. Twelve IRIS patients (75%)
were alive at 9 months’ follow-up, 2 patients showed marked
cognitive impairment, 1 patient defaulted study follow-up but
was alive, and 1 had marked cognitive impairment, residual
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Figure 2. Serial cerebrospinal ﬂuid (CSF) ﬁndings in patients who developed tuberculous meningitis immune reconstitution inﬂammatory syndrome
(left), and those who did not (right), including protein concentrations (A), CSF to blood glucose ratios (B ), neutrophil counts (C ), and lymphocyte counts
(D ). Signiﬁcant differences (P < .05) between time points within groups are indicated. Abbreviations: ART; antiretroviral therapy, CSF cerebrospinal ﬂuid;
IRIS; immune reconstitution inﬂammatory syndrome; TBM, tuberculous meningitis.
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hemiparesis, and hearing impairment. Death occurred in 4
(25%) TBM-IRIS patients at 33, 53, 60, and 118 days after
TBM diagnosis and was related to TBM-IRIS in 2 patients.
The 2 other deaths were due to a road trafﬁc accident (n = 1)
and unknown cause (n = 1). Kaplan-Meier survival analysis by
TBM-IRIS vs non-IRIS (with a log-rank hypothesis test of the
difference in survival between these 2) was nonsigniﬁcant.
DISCUSSION
This is the ﬁrst prospective study of TBM-IRIS. In our cohort,
tuberculosis IRIS presenting as TBM-IRIS (47%), as well as
tuberculosis IRIS involving any organ system (56%), was more
frequent than in previous studies [2–4, 27]. Extrapulmonary
tuberculosis is a risk factor for tuberculosis IRIS [14, 28], and
our cohort included only patients with TBM. A shorter inter-
val between starting tuberculosis treatment and ART (which
was 2 weeks in our study) similarly increases the risk of tuber-
culosis IRIS [2–4]. The high TBM-IRIS incidence we observed
is striking considering that all TBM-IRIS patients were taking
prednisone (1.5 mg/kg/day) at time of ART initiation and 13
of these patients (81%) were taking prednisone (0.75–1.5 mg/
kg/day) at the time of developing TBM-IRIS. Adjunctive corti-
costeroids have been shown to reduce mortality in TBM and
tuberculosis pericarditis, presumably by reducing pathological
host immune responses [21, 29]. In paradoxical tuberculosis
IRIS, the symptomatic beneﬁt of corticosteroids was demon-
strated in a randomized trial in which prednisone was com-
pared to placebo [30]. For these reasons, we anticipated that
prednisone would decrease the risk of tuberculosis IRIS.
TBM-IRIS was associated with a poor outcome; 2 patients
(13%) died as a result of TBM-IRIS, all-cause mortality at 9
months was 25%, and 3 of 11 (27%) survivors examined at 9
months’ follow-up were severely disabled, compared with no
deaths and 3 of 17 (18%) patients with severe morbidity in the
non-TBM-IRIS group. Our ﬁndings are similar to a previous
study performed in neurological tuberculosis IRIS [8]. The
poor outcome in at least 44% of TBM-IRIS cases emphasizes
Figure 3. Predictive model for tuberculous meningitis immune reconstitution inﬂammatory syndrome (TBM-IRIS; patients depicted by gray triangles)
and non-TBM-IRIS (patients depicted by black circles). Tumor necrosis factor–α and interferon-γ concentrations (pg/mL) are reported. Darker gray
indicates greater probability of TBM-IRIS, while lighter gray indicates greater probability of not developing TBM-IRIS. Probabilities associated with
shading are indicated by the legend. The middle line indicates 50% chance of TBM-IRIS, while the upper and lower gray lines indicate probabilities of
90% and 10%, respectively. Observe that when using the median line to classify patients as TBM-IRIS or non-TBM-IRIS, all but 2 TBM-IRIS and 1 non-
TBM-IRIS patients are correctly classiﬁed. Several points in the lower left were moved marginally to the right so that all subjects are clearly identiﬁable.
Abbreviations: IFN, interferon; TNF, tumor necrosis factor.
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the need to predict and prevent, and improve the treatment of,
TBM-IRIS.
Low serum sodium concentration is associated with death
in HIV-associated TBM [31]. In our study, serum sodium
concentration was lower in TBM-IRIS patients compared with
non-TBM-IRIS patients at the time of TBM diagnosis. This
may reﬂect the higher degree of tuberculosis dissemination
observed in TBM-IRIS patients, which could have contributed
to their risk of developing TBM-IRIS.
Our ﬁnding of an association between higher CSF neutro-
phils at TBM presentation and subsequent development of
TBM-IRIS provides important and novel insight into the path-
ogenesis of tuberculosis IRIS. Not only were neutrophil counts
higher in TBM-IRIS patients compared with non-TBM-IRIS
patients, but neutrophil percentages for individual patients
were similarly raised in TBM-IRIS. The neutrophil counts
showed dynamic ﬂuctuations over time in TBM-IRIS patients
with a marked decrease on tuberculosis treatment, and a strik-
ing increase at TBM-IRIS onset. Similar changes in lympho-
cyte counts were not observed. Studies of tuberculosis IRIS
have hitherto focused on the contribution of helper T-cell
type 1 lymphocyte responses [32, 33]. However, a role for
myeloid cells in tuberculosis IRIS is suggested by a case report
of a patient who died from unmasking pulmonary tuberculosis
IRIS; postmortem histological examination of diseased lung
showed a marked macrophage inﬁltrate [34]. We have found
cytokines of predominantly myeloid origin (IL-6 and TNF-α)
to be consistently elevated in patients with tuberculosis IRIS,
compared with those who did not develop IRIS [23]. Oliver
et al [6] also reported an association between plasma cytokines
(interleukin 18) and chemokines (CXCL-10) of the innate
immune system and tuberculosis IRIS. In an animal model,
immune reconstitution following transfer of mycobacteria-
speciﬁc CD4 T cells to T-cell–deﬁcient mice infected with
Mycobacterium avium was associated with marked increases
of both blood and lung CD11b cells (likely representing in-
ﬂammatory monocytes and neutrophils) [35]. Our results
suggest that neutrophils contribute to tuberculosis IRIS patho-
genesis. The combination of high CSF TNF-α and low IFN-γ
concentrations at the time of TBM diagnosis predicted TBM-
IRIS in this cohort. Simmons et al [36] reported a negative
correlation between CSF IFN-γ and mortality in HIV-infected
patients with TBM. Conversely, a positive correlation was
found between CSF IFN-γ and TNF-α concentrations and
TBM disease severity by others [37].
Several studies have shown an association between dissemi-
nated and extrapulmonary tuberculosis and subsequent tuber-
culosis IRIS [14, 28, 38, 39]. At TBM diagnosis, CSF M.
tuberculosis culture positivity, which reﬂects mycobacterial
antigen load, was a major risk factor for developing TBM-IRIS
(RR = 9.3). Furthermore, 7 TBM-IRIS patients (44%) were
persistently CSF M. tuberculosis culture positive after 2 weeks
of tuberculosis treatment and 2 patients (13%) remained
culture positive after 4 weeks of tuberculosis treatment. This
strongly supports the inference that a high M. tuberculosis ba-
cillary load at time of starting ART is a risk factor for tubercu-
losis IRIS [40]. The ﬁndings suggest it important to optimize
tuberculosis treatment prior to starting ART in patients at
high risk of developing TBM-IRIS.
We acknowledge several limitations. Because of the relative-
ly small sample size, the study may not have been powered to
detect further differences between IRIS and non-TBM-IRIS
patients. Only patients with less severe disease (BMRC TBM
grade 1 and 2) and those without contraindications to lumbar
puncture were enrolled, resulting in the exclusion of a signiﬁ-
cant proportion of TBM patients presenting in our setting
[41]; our results may therefore not be generalizable to ART-
naive patients presenting with severe HIV-associated TBM.
The model to predict TBM-IRIS needs further validation and
exploration with independent data.
In conclusion TBM-IRIS complicated the course of treat-
ment of HIV-associated TBM in nearly half our patients,
despite the use of adjunctive corticosteroid therapy. The mani-
festations were severe, fatal in 2 cases. The occurrence of
TBM-IRIS associated with CSF M. tuberculosis culture positiv-
ity and a high neutrophil count at both baseline and at the
time of TBM-IRIS. The baseline relationship between CSF
TNF-α and IFN-γ predicted TBM-IRIS. These observations
provide novel insight into the pathogenesis of this condition
and provide rationale to individualize ART beyond 2 weeks in
this devastating, partly iatrogenic, condition.
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